DSD-C092

46,XY DSD · 46,XY · DSD-C092

DSD-C092 · 46,XY DSD · 2020

Genes AR, CYP21A2, HSD17B3, HSD3B2, LHCGR, MAP3K1, WT1 · Karyotype 46,XY · Phenotypes HPO:0000047, Hypospadias (HP:0000047)

Neonate; clinical photograph taken at 6 weeks · 46,XY undervirilization, which the authors speculate is related to transient disruption of androgen synthesis and/or action from prolonged high-dose nystatin combination exposure during pregnancy.

Images · 1

Case fields and evidence

Category

46,XY DSD

Age

Neonate; clinical photograph taken at 6 weeks

Sex

46,XY, raised male

Karyotype

46,XY

Genetics

AR, CYP21A2, HSD17B3, HSD3B2, LHCGR, MAP3K1, WT1

Phenotypes

Hypospadias (HP:0000047)

Diagnosis

Neonate; clinical photograph taken at 6 weeks · 46,XY undervirilization, which the authors speculate is related to transient disruption of androgen synthesis and/or action from prolonged high-dose nystatin combination exposure during pregnancy.

Follow-up

At 8 months ACTH and hCG stimulation responses were normal; at 15 months the penis measured about 3×1.5 cm.

General phenotype

No obvious skeletal abnormalities apart from the external genitalia.

Imaging

Pelvic ultrasound showed no Mullerian structures.

Laboratory findings

17-OHP: 516 ng/dL (ref <360; time point: day 1 of life); newborn screening 17-OHP: 304 ng/mL (ref <35; time point: day 3 of life); ACTH-stimulation cortisol: 10 µg/dL (ref: limited interpretation in preterm; time point: day 3 of life); sodium: 134 mmol/L (ref: not reported; time point: day 12 of life); potassium: 6.9 mmol/L (ref: not reported; time point: day 12 of life); renin activity: 174 ng/mL/h (ref: not reported; time point: day 12 of life); mini-puberty testosterone: 83.4 ng/dL (ref: consistent with mini-puberty; time point: corrected age 2 mo 3 wk); 8-month post-hCG testosterone: 587 ng/dL (ref: normal response; time point: hCG day 4); 8-month post-hCG DHT: 111 ng/dL (ref: normal response; time point: hCG day 4)

Management

An outside hospital had given hydrocortisone, fludrocortisone, and salt supplementation for presumed adrenal dysfunction, gradually discontinued from 5-8 months; hypospadias repair and curvature correction at 10 months.

Pathology

Not reported.

Evidence level

See source

Clinical history

See source

Perinatal history

See source

Family history

See source

Growth and development

See source

External genital examination

See source

Limitations

See source

Cite this resource

DSD Research Library | 46,XY DSD · 46,XY · DSD-C092 | v1.4.0 | 2026-11-17 | https://dsdatlas.com/en/cases/DSD-C092?version=v1.4.0